GlucoModicum

GlucoModicum develops needle-free glucose monitoring technology using proprietary magnetohydrodynamic (MHD) technology, aiming to radically change how people monitor their health with precise, accessible, and needle-free solutions. The company was founded in 2018 as a spinout of the University of Helsinki and combines an experienced, multi-disciplinary in-house team with world-class partners to deliver groundbreaking solutions for personal biomarker monitoring. GlucoModicum's first product is Sofio, a modular, single-day, non-invasive, wearable glucose monitor for patients suffering from diabetes. Sofio is built on the company's MHD technology platform and offers clear glucose insights without needles and without long-term sensor commitments, designed for use on the days when patients need monitoring. The magnetohydrodynamic approach represents a fundamentally different method of glucose measurement compared to traditional invasive finger-prick tests or continuous glucose monitors that use needle-based sensors inserted under the skin. GlucoModicum's technology combines science, engineering, medicine, and manufacturing expertise to deliver needle-free glucose monitoring at scale. The company's multi-disciplinary team spans clinical research, engineering, and industrial development, working to bring non-invasive glucose monitoring to people in need as quickly as possible. The MHD platform has potential applications beyond glucose monitoring, creating solutions for personal biomarker monitoring more broadly. Founded in 2018 and headquartered in Helsinki, Finland, GlucoModicum has raised $1.4M in seed funding from investors including Abo Akademi University, University of Helsinki, EIC Fund, Europa, and Proxy Ventures.

Wearable Technology > Health and Wellness Devices > Diabetes Monitoring,

Disease Self Management > Diabetes > Monitoring > Glucose > Device > Wearable,

Diabetes > Medical Devices > Monitoring Devices > CGM > Non-Invasive